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both dopamine and serotonin, further evidence consis-
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tine’s effect was inhibited by the selective DAT inhibitor
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accumulated by DAT. The authors thus conclude that
when SERT is blocked by SSRIs, serotonin acts as a
false transmitter in dopamine neurons. Experiments in
vivo suggest that the effect may require several days
of administration, which could underlie the well-known
delay in full therapeutic benefit of these drugs. And to
bring the story full circle, they found that the MAO in-
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The data clearly indicate that, at least under some
conditions, both major classes of antidepressants
cause serotonin to act as false transmitter in dopamine
neurons. It is not yet known if such serotonin release
by dopamine neurons contributes to the therapeutic ef-
fect of these agents, and it would be very interesting to
know whether inhibition of DAT blocks the antidepres-
sant effects of SSRIs. The Dani lab, in the meantime,
can take credit for an elegant proof of a phenomenon
that may underlie the effects, and perhaps the delayed
response, for the many patients who take these drugs.
And well in time for the 50th anniversary of Hughes’
and Brodie’s seminal discovery.DOI 10.1016/j.neuron.2005.03.013
CAPS in Search of a
Lost Function
Ca2+-dependent activator protein for secretion (CAPS)
is an evolutionarily conserved secretory protein that
was previously thought to mediate Ca2+-triggered
fusion of dense-core vesicles. In an elegant study of
CAPS1-deficient mice, Speidel et al. (this issue of
Neuron) now show that CAPS function may have
been misunderstood. CAPS appears to act upstream
of fusion in the biogenesis or maintenance of mature
secretory vesicles, raising the possibility of a com-
pletely new type of function for an essential compo-
nent of the secretory machinery.
CAPS was discovered independently in C. elegans as
the unc-31 gene that is required for synaptic transmis-
sion (Livingstone, 1991) and in PC12 cells as an essen-
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3tial component of the Ca2+-triggering machinery for ex-
ocytosis (Walent et al., 1992). CAPS is an w140 kDa
protein that contains two major identifiable domains: a
central PH domain that binds to phospholipids, and a
C-terminal region that is homologous to Munc13s, pro-
teins that are involved in synaptic vesicle priming
(Speidel et al., 2003). CAPS is highly conserved in evo-
lution; a single CAPS isoform is expressed in inverte-
brates, whereas two closely related isoforms are pro-
duced in vertebrates (referred to as CAPS1 and CAPS2;
Speidel et al., 2003). CAPS forms dimers and interacts
with phospholipids, suggesting a membrane-associ-
ated function (Walent et al., 1992). CAPS is primarily
expressed in neurons and neuroendocrine cells, al-
though nonneuronal tissues such as liver contain signif-
icant levels (Walent et al., 1992; Speidel et al., 2003).
The seminal description of CAPS as an essential
factor in the Ca2+-triggered release of norepinephrine
from PC12 cells (Walent et al., 1992) spawned a series
of studies on the role of CAPS in secretion in neuroen-
docrine cells. These studies led to the widely accepted
conclusion that CAPS specifically mediates the Ca2+-
dependent exocytosis of large dense-core vesicles
(LDCVs) and other dense-core vesicles (e.g., see Gri-
shanin et al., 2004; Rupnik et al., 2000; Elhamdani et
al., 1999; Tandon et al., 1998). A closer look, however,
reveals that this conclusion may not be entirely certain.
For example, the analysis of CAPS mutants in Drosoph-
ila (Renden et al., 2001) uncovered a selective decrease
in evoked glutamatergic synaptic transmission at the
neuromuscular junction of CAPS-deficient flies. In this
study, the only evidence for a change in dense-core
vesicle exocytosis was a moderate increase in the den-
sity of LDCVs in nerve terminals; however, the number
of synaptic vesicles per active zone was also increased
significantly in CAPS-deficient flies, casting doubt on a
specific role for CAPS in LDCV exocytosis.
The new results of Speidel et al. (2005) (this issue of
Neuron), produced by a technical tour-de-force, throw
fresh light on CAPS function. Speidel et al. generated
KO mice lacking CAPS1. Homozygous mutant mice
died within 30 min after birth, but exhibited no obvious
developmental or biochemical abnormalities. The authors
then performed an in-depth analysis of exocytosis in
chromaffin cells at two developmental stages: embryonic
homozygous mutant mice (at day E19, just before
birth), and adolescent heterozygous mutant mice (at
day P30). It should be stated at the outset that Speidel
et al. do not propose to present a definitive function for
CAPS. With the results of Speidel et al. available, we
still don't know what CAPS does, but we know much
more about what it does not do, and we have definitive
ideas about what it might do. These intriguing results
will stimulate the field and initiate many new studies on
this fascinating protein.
Speidel et al. show that in homozygous CAPS1 KO
mice at E19, chromaffin cells exhibited no change in
the amplitude or rate of Ca2+-triggered exocytosis. By
itself, this results is not surprising, since CAPS2 is ex-
pressed at 8-fold higher levels than CAPS1 in the adre-
nals at this stage of development, and thus the lack of
a phenotype in exocytosis could have been simply due
to redundancy. Strikingly, however, using amperometry,Speidel et al. found that only 40% of the granules un-
dergoing exocytosis were actually filled with catechola-
mines! This unexpected phenotype was not due to a
developmental defect, because the phenotype could
be rescued by expression of recombinant CAPS1.
Quantitative electron microscopy of the CAPS1-defi-
cient cells uncovered no changes—in particular, the
number and appearance of chromaffin granules were
not altered. Biochemically, the levels of adrenaline and
noradrenaline were normal, but the concentration of the
metabolite DOPEG that is derived from adrenaline and
noradrenaline was increased 3- to 4-fold, suggesting
that noradrenaline and adrenaline turn over much more
rapidly in the CAPS1-deficient cells than in control
cells.
Overall, the results obtained by Speidel et al. in mu-
tant embryonic chromaffin cells point toward an essen-
tial role for CAPS1 in maintaining stable secretory vesi-
cles that are filled with neurotransmitters. Empty
secretory vesicles were previously observed at a low
frequency (7%) in wild-type chromaffin cells, but in-
creased to >40% after treatment of cells with the cate-
cholamine uptake inhibitor reserpine (Tabares et al.,
2001). Similar to the results reported by Speidel et al.,
the vesicles characterized by Tabares et al. were also
either completely full or completely empty. Thus,
Speidel et al. conclusively show that in embryonic cells,
CAPS1 in some manner is essential for the normal fill-
ing of vesicles with catecholamines.
The phenotype observed in young adult heterozy-
gous CAPS1-deficient chromaffin cells was quite dif-
ferent from that of embryonic homozygous mutant
cells. The heterozygous mutant cells (which have ap-
proximately half the wild-type levels of CAPS1) exhib-
ited a moderate decrease (w30%) in the amplitude of
the fast and slow component of the exocytosis, but no
change in the kinetics of release. Amperometry showed
that all granules were filled with catecholamines at
wild-type levels in the heterozygous mutant cells.
Electron microscopy demonstrated that the mutant
chromaffin cells were overall normal, but uncovered a
single change, namely a modest but significant de-
crease (w30%) in the density of vesicles close (<200
nm) to the plasma membrane.
At first glance, the phenotypes of the homozygous
embryonic and the heterozygous adolescent chro-
maffin cells appear incompatible, but they can be rec-
onciled by the simple assumption that CAPS normally
functions in filling or maintaining filled chromaffin gran-
ules and that in mature cells empty granules are largely
eliminated by a quality control mechanism, whereas in
embryonic cells such a quality control mechanism does
not yet operate. The analysis of the CAPS1-deficient
chromaffin cells thus confirms that CAPS1 has a func-
tion in secretion, although it provides no evidence that
this function is related to Ca2+ triggering. Normal
CAPS1 levels clearly are not essential for normal fusion,
and CAPS1 is unlikely to play a role in the fusion pore.
This result highlights the sensitivity of fusion pores to
overexpression, because CAPS1 is yet another protein
in a long list of molecules that when overexpressed al-
ter fusion pores without directly participating in fusion
(e.g., see synaptotagmin 1, which alters fusion-pore
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4Gopening upon overexpression, but does not normally
Cparticipate in determining the kinetics of fusion-pore
4opening [reviewed in Su¨dhof, 2004]). The effects of
LCAPS1 overexpression are most likely due to the fact
d
that any change in membrane composition or tension, U
be it ever so slight, will change fusion pores, and so, R
many overexpressed transfected proteins, even pro- G
teins that are unrelated to secretion, are likely to alter 4
fusion pores. In addition, the data by Speidel et al. R
G(2005) exclude a function for CAPS in diverse pro-
5cesses such as Ca2+ triggering of exocytosis or endo-
Scytosis.
tIt is thus safe to say at this point that CAPS is impor-
2tant for secretion, but it is unsafe to say what exactly it
Sis important for. Clearly, the original notion of a clearcut
R
function in the Ca2+-dependent exocytosis of LDCVs is (
untenable. However, a specific role in catecholamine
S
storage as such is also unlikely. Although such a role
T
would explain why vesicles in the CAPS1 KO mice are J
empty (Speidel et al., 2005) and why recombinant T
CAPS1 is required for norepinephrine release from a
semi-intact PC12 cells (since empty vesicles would ap- W
pear not to exocytose), such a function is inconsistent
Dwith the widespread presence of CAPS in all syn-
apses—most of which do not secrete catechola-
mines—and even in tissues like liver, which is not
known for Ca2+-triggered exocytosis (Speidel et al.,
2003).
Can a unifying hypothesis of CAPS function that sat-
isfies all available data be postulated? A general role in
the stabilization of exocytic compartments seems im-
probable because one would then expect that the num-
ber and/or shape of secretory vesicles should be al-
tered. However, it is possible that CAPS functions in
maintaining the pH gradient across the membrane of
secretory vesicles as they wait to be exocytosed. An-
other possibility is that CAPS is important for stabilizing
the phospholipid bilayers of secretory vesicles, al-
though in such a case a change in the ultrastructure
of chromaffin cells would have been expected. A third
possibility is that CAPS functions in the trafficking of
secretory vesicles that have undergone endocytosis
and are being recycled for exocytosis. For example,
empty chromaffin granules may accumulate if vesicles
are not properly prepared for refilling after endocytosis.
Solving CAPS function will remain a major challenge
that is certain to generate many additional surprises
and important new insights.
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